Clinical Trials
3 trialsNCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT01881230 2019-02-21
tnAcity
Celgene
Phase 2/3 Completed
NCT01204437 2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3 Completed